ID

34887

Beschreibung

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02456207

Link

https://clinicaltrials.gov/show/NCT02456207

Stichworte

Versionen (1)
  1. 02.02.19 02.02.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

2. Februar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

Englisch

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. aged from 18 to 75 years;
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
2. having histologically confirmed nhl expressing cd20 antigen;
Beschreibung

Non-Hodgkin Lymphoma CD20 expressing

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0024305
UMLS CUI [1,2]
C3888518
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
Beschreibung

In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C1514463
UMLS CUI [2,1]
C0677874
UMLS CUI [2,2]
C0087130
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1514463
4. ecog performance status of 0 to 1
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
5. expected survival of at least ≥ 3 months;
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
Beschreibung

rituximab | Anti-CD20 Antibody

Datentyp

boolean

Alias
UMLS CUI [1]
C0393022
UMLS CUI [2]
C3891557
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
Beschreibung

Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205156
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C0600688
UMLS CUI [3,3]
C2004454
UMLS CUI [3,4]
C0332268
3. participating in other clinical trial within 30 days before enrolment;
Beschreibung

Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
Beschreibung

Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0221099
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
UMLS CUI [5]
C0518015
UMLS CUI [6]
C0086565
UMLS CUI [7]
C0741494
UMLS CUI [8]
C0151904
UMLS CUI [9]
C0151905
UMLS CUI [10]
C3279454
UMLS CUI [11]
C0700225
UMLS CUI [12]
C0853225
UMLS CUI [13]
C0240671
UMLS CUI [14]
C1837411
UMLS CUI [15,1]
C1705847
UMLS CUI [15,2]
C0441509
5. had received live vaccine within 4 weeks prior to study entry;
Beschreibung

Vaccines, Attenuated

Datentyp

boolean

Alias
UMLS CUI [1]
C0042211
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
Beschreibung

Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms

Datentyp

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2]
C0742472
UMLS CUI [3]
C0085090
UMLS CUI [4]
C0029118
UMLS CUI [5,1]
C0012634
UMLS CUI [5,2]
C0205404
UMLS CUI [5,3]
C0332300
UMLS CUI [5,4]
C0006826
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
Beschreibung

Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0166049
UMLS CUI [1,2]
C0521143
UMLS CUI [2,1]
C0019683
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019168
UMLS CUI [3,2]
C0521143
UMLS CUI [4,1]
C0948759
UMLS CUI [4,2]
C0521143
UMLS CUI [5,1]
C1256114
UMLS CUI [5,2]
C1513916
UMLS CUI [5,3]
C0683607
UMLS CUI [6,1]
C0919711
UMLS CUI [6,2]
C0683607
8. recent major surgery (within 28 days prior to study entry );
Beschreibung

Major surgery

Datentyp

boolean

Alias
UMLS CUI [1]
C0679637
9. with a history of allergic reaction or protein product allergy including murine proteins;
Beschreibung

Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0033684
UMLS CUI [2]
C1112677
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C1699668
10. pregnant or lactating or not accepted birth control methods including male patients.
Beschreibung

Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1548437
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility B-cell Non Hodgkin's Lymphoma NCT02456207

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. aged from 18 to 75 years;
boolean
C0001779 (UMLS CUI [1])
Non-Hodgkin Lymphoma CD20 expressing
Item
2. having histologically confirmed nhl expressing cd20 antigen;
boolean
C0024305 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
In complete remission Post Prior Therapy | Complete remission Uncertain Post Prior Therapy
Item
3. having obtained cr (complete remission) or cru (uncertain complete remisson) after the prior therapy;
boolean
C0677874 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C0677874 (UMLS CUI [2,1])
C0087130 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1514463 (UMLS CUI [2,4])
ECOG performance status
Item
4. ecog performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
5. expected survival of at least ≥ 3 months;
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
6. signed an informed consent form which was approved by the institutional review board of the respective medical center .
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
rituximab | Anti-CD20 Antibody
Item
1. had received rituximab or other anti-cd20(+) monoclonal antibody treatment within 1 year before enrollment;
boolean
C0393022 (UMLS CUI [1])
C3891557 (UMLS CUI [2])
Cancer treatment Previous | Adrenal Cortex Hormones Previous | Prior Therapy Toxicity Recovery Lacking
Item
2. having to be at least 4 weeks beyond prior anticancer therapy including corticosteroid, or have not recovered from significant toxicities of prior therapy;
boolean
C0920425 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C1514463 (UMLS CUI [3,1])
C0600688 (UMLS CUI [3,2])
C2004454 (UMLS CUI [3,3])
C0332268 (UMLS CUI [3,4])
Study Subject Participation Status
Item
3. participating in other clinical trial within 30 days before enrolment;
boolean
C2348568 (UMLS CUI [1])
Hematologic function Impaired | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement | Liver Dysfunction | Elevated total bilirubin | Aspartate aminotransferase increased | Alanine aminotransferase increased | Renal dysfunction | Serum creatinine raised | INR raised | Partial thromboplastin time increased | Prolonged activated partial thromboplastin time (aPTT) | Exception Coagulation therapy
Item
4. with serious hematologic dysfunction (white blood cell count of <3.0×103/ul; absolute neutrophil count of <1.5×103/ ul; platelet count of < 75×103/ul; hemoglobin level of < 8.0 g/dl); hepatic dysfunction (total bilirubin level of > 1.5×uln; aspartate amino transferase (ast) and alanine amino transferase (alt) levels of >2.5 × uln; renal dysfunction (serum creatinine level of > 1.5×uln ); and international normalized ratio (inr) and partial thromboplastin time or activated partial thromboplastin time (aptt) > 1.5 × uln (unless on therapeutic coagulation);
boolean
C0221130 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C0518015 (UMLS CUI [5])
C0086565 (UMLS CUI [6])
C0741494 (UMLS CUI [7])
C0151904 (UMLS CUI [8])
C0151905 (UMLS CUI [9])
C3279454 (UMLS CUI [10])
C0700225 (UMLS CUI [11])
C0853225 (UMLS CUI [12])
C0240671 (UMLS CUI [13])
C1837411 (UMLS CUI [14])
C1705847 (UMLS CUI [15,1])
C0441509 (UMLS CUI [15,2])
Vaccines, Attenuated
Item
5. had received live vaccine within 4 weeks prior to study entry;
boolean
C0042211 (UMLS CUI [1])
Cancer Other | Central nervous system lymphoma | Lymphoma, AIDS-Related | Opportunistic Infection | Disease Serious Except Malignant Neoplasms
Item
6. with other malignancies ; or central nervous system (cns) lymphoma, aids-related lymphoma; or active opportunistic infection, a serious nonmalignant disease;
boolean
C1707251 (UMLS CUI [1])
C0742472 (UMLS CUI [2])
C0085090 (UMLS CUI [3])
C0029118 (UMLS CUI [4])
C0012634 (UMLS CUI [5,1])
C0205404 (UMLS CUI [5,2])
C0332300 (UMLS CUI [5,3])
C0006826 (UMLS CUI [5,4])
Hepatitis C Antibody Seropositive | HIV Antibody Seropositive | Hepatitis B Surface Antigens Seropositive | Anti-HBc antibody Seropositive | Hbv DNA Test Negative allowed | Hepatitis B surface antigen negative allowed
Item
7. seropositive for hcv antibody, or hiv antibody, or hepatitis b virus surface antigen (hbsag). hbc antibody seropositive, but hbv dna and hbsag negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of hbv antiviral therapy, and provided they agree to receive treatment as indicated,
boolean
C0166049 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0019683 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019168 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0948759 (UMLS CUI [4,1])
C0521143 (UMLS CUI [4,2])
C1256114 (UMLS CUI [5,1])
C1513916 (UMLS CUI [5,2])
C0683607 (UMLS CUI [5,3])
C0919711 (UMLS CUI [6,1])
C0683607 (UMLS CUI [6,2])
Major surgery
Item
8. recent major surgery (within 28 days prior to study entry );
boolean
C0679637 (UMLS CUI [1])
Allergic Reaction Proteins | Protein allergy | Hypersensitivity Murine protein
Item
9. with a history of allergic reaction or protein product allergy including murine proteins;
boolean
C1527304 (UMLS CUI [1,1])
C0033684 (UMLS CUI [1,2])
C1112677 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C1699668 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Gender Contraceptive methods Rejected
Item
10. pregnant or lactating or not accepted birth control methods including male patients.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1548437 (UMLS CUI [3,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video